 PLANO, Texas, May 19, 2021 GLOBE NEWSWIRE -- Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, or we, a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 Division of the U.S. Food and Drug Administration FDA stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreichs ataxia FA. The Division suggested that the Company withdraw the current meeting request for a Type C meeting and instead request a pre-NDA meeting, which the Division will grant upon receipt. The Division asked the Company to focus the new briefing package on questions, issues, and needs applicable to a pre-NDA meeting. As requested by the FDA, the Company plans to withdraw the current request for a Type C meeting and submit a request for a pre-NDA meeting as soon as practicable. 